AngioDynamics Taps Former CryoCath Chief Keltjens For CEO Slot
This article was originally published in The Gray Sheet
Executive Summary
Incoming AngioDynamics CEO Jan Keltjens will draw on his 20-plus years of device industry leadership experience, including as former chief exec of CryoCath Technologies, to shepherd "the next level" of growth at the company
You may also be interested in...
AngioDynamics Oncology Surgery Biz Helps Drive 13% Sales Growth
AngioDynamics' sales advanced 13% to $50.1 million in the firm's most recent fiscal quarter, aided by strong growth in its Oncology/Surgery business, the firm reported Oct. 6
AngioDynamics Oncology Surgery Biz Helps Drive 13% Sales Growth
AngioDynamics' sales advanced 13% to $50.1 million in the firm's most recent fiscal quarter, aided by strong growth in its Oncology/Surgery business, the firm reported Oct. 6
People In Brief
AngioDynamics leadership transition: Eamonn Hobbs, president and CEO of interventional radiology and oncology device maker AngioDynamics, says he will relinquish his role to become vice chairman of the board of directors, once the company has identified a "world class candidate" to lead the company. Hobbs, who co-founded the company 20 years ago, suggests, in a Dec. 3 announcement, that his strengths are primarily "entrepreneurial" and the firm now needs a leader to focus more exclusively on operational and administrative activities. In addition to a CEO, the firm is searching for an executive to manage its oncology/surgery business unit. On Dec. 9, it appointed Michael Sharp, formerly of image-based orthopedics company ConforMIS, as VP of regulatory, quality and clinical affairs